Clinical Trial Update: AC-1204 Long-term Efficacy Response Trial (ALERT Protocol) [Phase 2, Phase 3]

View source ↗

Summary

Cerecin has withdrawn the long-term efficacy ALERT trial (AC-1204) in Alzheimer's disease after Phase 2/3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AC-1204

Snippet

Sponsor: Cerecin | Conditions: Alzheimer's Disease | Phase 2, Phase 3 | Status: WITHDRAWN